Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. [electronic resource]
Producer: 19981130Description: 3601-6 p. digitalISSN:- 0732-183X
- Adolescent
- Adult
- Age Factors
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bleomycin -- administration & dosage
- CD4 Lymphocyte Count
- Child
- Cyclophosphamide -- administration & dosage
- Dexamethasone -- administration & dosage
- Doxorubicin -- administration & dosage
- Granulocyte-Macrophage Colony-Stimulating Factor -- administration & dosage
- Humans
- Leucovorin -- administration & dosage
- Lymphoma, AIDS-Related -- mortality
- Methotrexate -- administration & dosage
- Middle Aged
- Multivariate Analysis
- Prognosis
- Vincristine -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.